137 related articles for article (PubMed ID: 35641261)
1. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
[TBL] [Abstract][Full Text] [Related]
2. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
3. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
[TBL] [Abstract][Full Text] [Related]
4. Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles Received, Cumulative Dose Intensity, and Survival in Resected Early-stage Pancreas Cancer.
Wu VS; Elshami M; Stitzel HJ; Lee JJ; Hue JJ; Kyasaram RK; Hardacre JM; Ammori JB; Winter JM; Selfridge JE; Mohamed A; Chakrabarti S; Bajor D; Mahipal A; Ocuin LM
Ann Surg; 2023 Oct; 278(4):e677-e684. PubMed ID: 37071769
[TBL] [Abstract][Full Text] [Related]
5. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
6. Radiographic duodenal invasion is associated with poor prognosis and early recurrence in patients with pancreatic ductal adenocarcinoma.
Miyazawa M; Hirono S; Kawai M; Okada KI; Kitahata Y; Motobayashi H; Sato M; Yoshimura T; Ueno M; Hayami S; Miyamoto A; Shimizu A; Yamaue H
Eur J Surg Oncol; 2023 Oct; 49(10):106960. PubMed ID: 37353425
[TBL] [Abstract][Full Text] [Related]
7. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
[TBL] [Abstract][Full Text] [Related]
9. Geriatric Nutritional Risk Index Predicts Tolerability of S-1 as Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Sakamoto A; Funamizu N; Shine M; Uraoka M; Nagaoka T; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
Pancreas; 2023 Mar; 52(3):e196-e202. PubMed ID: 37824399
[TBL] [Abstract][Full Text] [Related]
10. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
11. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
14. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
[TBL] [Abstract][Full Text] [Related]
15. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H
Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789
[TBL] [Abstract][Full Text] [Related]
18. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
20. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
Tomimaru Y; Eguchi H; Shimomura Y; Kitamura T; Inoue Y; Nagakawa Y; Ohba A; Onoe S; Unno M; Hashimoto D; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Uemura K; Kimura Y; Satoi S; Takeyama Y;
J Gastroenterol; 2023 Aug; 58(8):790-799. PubMed ID: 37329351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
